Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA, Financial Terms Undisclosed

Author: Benzinga Newsdesk | July 01, 2024 07:14am

Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (NASDAQ:QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company. Under the terms of the agreement, Genezen will enter into strategic supply agreements for uniQure's clinical portfolio and CSL's commercial HEMGENIX® product, the first one-time gene therapy approved in the U.S. and Europe for the treatment of adults with severe and moderately severe Hemophilia B. Located just outside of Boston, the Lexington site is a commercially-licensed viral vector facility, enabling Genezen to support customers from preclinical development programs through late-phase and commercial manufacturing. The facility also includes a state-of-the-art laboratory space and pilot plant that will serve as Genezen's global AAV center of excellence. With industry-leading infrastructure and a proven track record, the Lexington site will complement Genezen's existing clinical manufacturing operations and talented team in Indianapolis, IN.

Posted In: QURE